Lanréotide Viatris Lp

Lanreotide, the active ingredient in Lanréotide Viatris Lp, is a somatostatin analog presented as a long‑acting injectable suspension for subcutaneous use. It treats acromegaly and neuroendocrine tumors in adult patients.

GNH USA supplies Lanréotide Viatris Lp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanreotide is employed in endocrine and neuroendocrine disorders where somatostatin pathways are targeted.

Acromegaly: reduces excess growth hormone secretion and normalizes IGF‑1 levels, helping control disease progression and associated symptoms. Neuroendocrine tumors (carcinoid syndrome): controls hormone‑related flushing and diarrhea while potentially slowing tumor growth and improving quality of life.

Lanreotide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema - Diarrhea or loose stools - Nausea and abdominal discomfort - Hyperglycemia or altered glucose tolerance - Gallbladder sludge or stones - Headache

Serious or Rare Side Effects: - Acute pancreatitis - Severe hyperglycemia requiring medical intervention - Anaphylactic or severe allergic reactions - Cardiac arrhythmias or conduction abnormalities

Prior to initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood glucose monitoring: assess baseline and periodic glucose levels, especially in diabetic patients. - Gallbladder assessment: consider ultrasound in patients with a history of gallstones. - Tumor response: regularly evaluate disease markers and imaging to adjust therapy. - Renal/hepatic impairment: dose adjustments may be needed in severe dysfunction. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Concomitant use with cyclosporine: may increase cyclosporine levels. - Co‑administration with other somatostatin analogs: additive hormonal suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: may require dose adjustments due to altered glucose control. - Estrogen‑containing therapies: increased risk of gallstone formation. - Diuretics: monitor electrolyte balance as lanreotide can affect renal handling of water and salts.